EXPLORE G2D2’S COLLABORATIVE APPROACH

INCREASE OUR CHANCE TO SUCCEED USING HUMAN
BIOLOGY DATA

Despite many successes in treating animal models of Alzheimer’s disease (AD), this hasn’t translated to humans. We believe that by guiding our drug discovery and development efforts using human biology data, we’ll increase our chance to succeed in developing novel therapies for patients.

FULLY UNDERSTAND THE GENETICS OF AD

Over the last decade, the genetic architecture of late-onset AD has been extensively characterized, revealing immune genes, pathways and cell types (including microglia) that weren’t previously thought to play a major role in disease. We’re focusing our drug discovery efforts on understanding how to optimally target these pathways.

COLLABORATE WITH EXTERNAL ACADEMIC LABS
AND CONSORTIA

Our group analyzes high-dimensional genetic and other human data, both internally and in collaboration with external groups. We then work closely with G2D2 biologists and chemists to incorporate those insights into experiments.

INNOVATE THROUGH CUTTING-EDGE TECHNOLOGY PLATFORMS

AD human genetics reveal unconventional targets, frequently with minimal biological understanding or research history. Such targets frequently require the need to reactivate or enhance diminishing function in a disease state.

Novel therapeutics require a deep understanding of targets at a molecular level, and exploration of new therapeutic approaches.

To address these challenges, we build cutting-edge technology platforms combining structural biology, chemical biology, computational chemistry, novel assay development and compound screening automation.

ADVANCE SCIENCE THROUGH COLLABORATION

To deliver an innovative immunodementia drug to patients in an accelerated timeframe requires all talented minds to work together. We have established collaborations with leading laboratories around the world to accelerate the discovery process.

WE USE CUTTING-EDGE INNOVATIONS IN CHEMICAL AND STRUCTURAL BIOLOGY, COMPUTATIONAL CHEMISTRY, AND ASSAY DEVELOPMENT TO BRIDGE BIOLOGY AND CHEMISTRY — ALL GUIDED THROUGH THE LENS OF HUMAN GENETICS.

John Wang
Head, Discovery Sciences, G2D2

APPLY THE FULL POWER OF ORGANIC CHEMISTRY

Eisai’s rich history in natural products-based research has demonstrated that the areas of chemical space practically accessible to drug discovery are far greater than previously thought possible.

A TRACK RECORD IN CHEMICAL INNOVATION

Our scientists have discovered and developed several innovation solutions to complex drug discovery problems, including:

• The fully synthetic marine natural product-inspired therapeutic agent eribulin, consisting of a polycyclic ketal embedded in a 22-membered macro-cyclic ketone containing 19 stereo¬genic centers.
• Direct interrogation of genetic targets with stereodefined and topologically novel nucleic acids yielded an immunotherapeutic clinical candidate (E7766) and provides an example of our precision chemistry platform.

OUR PLATFORM APPLIES TARGETED SOLUTIONS — ACROSS A RANGE OF MODALITIES — THAT ARE SPECIFIC TO GENETICALLY DEFINED DRUG TARGETS. THE COMBINED POWER OF PRECISION CHEMISTRY, DATA SCIENCES AND HUMAN GENETICS WILL BE ESSENTIAL TO DEVELOP BREAKTHROUGH IMMUNODEMENTIA THERA¬PEUTICS.

Frank Fang
Deputy President & Head, Precision Chemistry, G2D2